ArticleIranian journal of medical sciences2025
Annexin A5 Protects SH-SY5Y Cells against L-Glutamate-Induced Cytotoxicity.
Article in Iranian journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recombinant Annexin A5 Alleviates Aluminum Chloride-Induced Cytotoxicity, Mitochondrial Dysfunction, and Apoptotic Signaling in SH-SY5Y Cells.Iranian journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: L- glutamate- induced neurotoxicity is linked to neuronal loss in neurodegenerative diseases and stroke. Annexin A5 (ANXA5) is a cytosolic protein that binds calcium in eukaryotic organisms. This study aimed to evaluate the protective effects of a recombinant ANXA5 against L-glutamate-induced cell death and mitochondrial dysfunction in SH-SY5Y cells. Methods: ANXA5 was expressed in Results: The findings revealed that L-glutamate reduced the cell viability of SH-SY5Y cells in a dose-dependent manner (P<0.001) (IC50=165 mM). Moreover, treating SH-SY5Y cells with 165 mM of L-glutamate increased MMP dissipation, enhanced Bax expression, and reduced the expression of Conclusion: The data suggest that ANXA5 can protect SH-SY5Y cells against glutamate-induced cell death and mitochondrial dysfunction, indicating its possible protective effect against glutamate-induced neurodegeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.